Volume 24, Number 1 (February 2017) The latest issue of Current Oncology is now available online. Please visit the following link to view full text a

   
CO-Header-new
Hot-off-the-Press

Volume 24, Number 1 (February 2017)

The latest issue of Current Oncology is now available online. Please visit the following link to view full text articles from this issue:
http://www.current-oncology.com/index.php/oncology/issue/current/showToc

CO-COVER-ISSUE

Highlights from this issue...

Exercise for people with cancer: a clinical practice guideline
R. Segal, C. Zwaal, E. Green, J.R. Tomasone, A. Loblaw, T. Petrella, The Exercise for People with Cancer Guideline Development Group

Listening through narratives: using a narrative approach when discussing fertility preservation options with young cancer patients
S.I.G. Roher, J. Gibson, B.E. Gibson, A.A. Gupta

A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma
D. MacDonald, T. Crosbie, A. Christofides, W. Assaily, J. Wiernikowski

Is there a sex effect in colon cancer? Disease characteristics, management, and outcomes in routine clinical practice
J.S. Quirt, S. Nanji, X. Wei, J.A. Flemming, C.M. Booth

Does adjuvant radiation therapy benefit women with small mammography-detected breast cancers?
K. Jerzak, N. Dudalski, K. Pritchard, P. Sun, S.A. Narod

Updates from the 2016 American Society of Hematology annual meeting: practice-changing studies in untreated follicular lymphoma
C. Owen, D. MacDonald, A. Aw, A. Christofides

***
Looking-Ahead

Upcoming in Current Oncology

The future table of contents for Current Oncology, Volume 24, Number 2 (April 2017) is now available. For the most up-to-date listing of scheduled papers, please visit the following link:
http://www.current-oncology.com/index.php/oncology/about/futureTOC

Highlights from this issue…

The Two Solitudes of Primary Care and Cancer Specialist Care: A collection of papers from CanIMPACT (Canadian Team to Improve Community-based Cancer Care along the Continuum), that describe and seek to understand the nature of the two solitudes within the Canadian context as well as initiatives that attempt to bridge the two solitudes.

***
publisher 1

We are pleased to announce that Current Oncology has partnered with the Canadian Association of Psychosocial Oncology (CAPO). The partnership will help promote relevant research, critical findings, and journal related news to CAPO members, and our readers will be kept informed of relevant CAPO activities, including conferences and important psychosocial oncology research. Other highlights of the partnership include:

Current Oncology is now the endorsed publication of the society
• Publication of CAPO Conference Abstracts and Practice Guidelines in Current Oncology
• Discounted author fees for CAPO members – we encourage members to consider publishing their important work related to psychosocial research and education in Current Oncology
Current Oncology to sponsor CAPO’s Student Travel Conference Award

We are excited to work with CAPO, and welcome and encourage other societies across Canada to partner with us as we continue our mission of educating and sharing knowledge with members of the Canadian oncology community. For more information about partnership opportunities, please contact Amanda Shand (Amanda_Shand@multi-med.com).

logo70

Multimed Inc.
Publisher of Current Oncology
www.multi-med.com

***
Editorial-Spotlight
MS Head Shot 2016

Matthew Seftel, MBChB MPH MRCP FRCPC
Associate Managing Editor (since January 2017)

Matthew Seftel is the department head of Haematology and Oncology at CancerCare Manitoba and the Section of Haematology/Oncology, Department of Internal Medicine, University of Manitoba. He is an associate professor at the University of Manitoba.

His medical degree is from the University of Cape Town South Africa with specialist diplomas in Internal Medicine and Hematology from the UK and Canada. He also holds a Masters in Public Health from Johns Hopkins University.

His research interests include leukemia epidemiology, as well as clinical trials in leukemia and lymphoma, including Blood and Marrow Transplantation. He is an investigator with the Canadian Cancer Trials Group (CCTG) and the Centre for International Blood and Marrow Transplant Research (CIBMTR).

***
Have-You-Heard

Current Oncology Welcomes Dr. Matthew Seftel to our Editorial Team

We are pleased to welcome Dr. Matthew Seftel (CancerCare Manitoba & University of Manitoba, Winnipeg, Manitoba) to the Editorial Team as our Associate Managing Editor. We are confident that with Dr. Seftel undertaking this new role, and in collaboration with members of the editorial office and team of Editors, that our journal will continue to strengthen and grow. To view Current Oncology’s full list of Editors, please click here.

Predatory Publishers are on the Rise

Predatory publishers are on the rise and exploit the open-access author-pays model. These publishers fool researchers into thinking they are legitimate publications as they resemble an online scholarly journal, list an Editorial board (often fabricated), and claim that articles are peer-reviewed. This rise in predatory publishers brings home the importance of working with a reputable publisher. Integrity, transparency and peer review are the cornerstones of scholarly publishing. When you receive an email inviting you to submit a manuscript to a scholarly journal, we encourage you to consider:

1. Is the journal's peer-review process clearly described?
2. Does the journal have a registered International Standard Serial Number (ISSN)?
3. Are the policies related to author fees clearly outlined on the website?
4. Is the journal indexed in reputable databases? If yes, verify a journal's claims to be indexed by a reputable database
5. Evaluate the quality of the articles previously published

***
Readers-Choice

Have you had the chance to view these Current Oncology “Most-Read” articles?

Most Read Articles in PubMed Central (January 2017)

Legalizing euthanasia or assisted suicide: the illusion of safeguards and controls
Pereira J.
Curr Oncol. 2011 Apr;18(2):e38-45

A user's guide to cannabinoid therapies in oncology
Maida V, Daeninck PJ
Curr Oncol. 2016 Dec;23(6):398-406. doi: 10.3747/co.23.3487. Epub 2016 Dec 21

Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases
Ali A, Goffin JR, Arnold A, Ellis PM
Curr Oncol. 2013 Aug;20(4):e300-6. doi: 10.3747/co.20.1481

Most Read Recently* Published Articles at www.current-oncology.com

Anticancer mechanisms of cannabinoids
Velasco G, Sánchez C, Guzmán M
Curr Oncol. 2016 Mar;23(Suppl 2):S23-32. doi: 10.3747/co.23.3080. Epub 2016 Mar 16.

Use of cannabinoids in cancer care: palliative care
Aggarwal SK.
Curr Oncol. 2016 Mar;23(Suppl 2):S33-6. doi: 10.3747/co.23.2962. Epub 2016 Mar 16.

Integrating cannabis into clinical cancer care
D.I. Abrams
Curr Oncol. 2016 Mar;23(Suppl 2):S8-14. doi: 10.3747/co.23.3099. Epub 2016 Mar 16.

*Published within past 12 months

***
Meeting-Alerts

Next Gen Immuno-Oncology Congress

March 13-14, 2017
London, UK

nex-gen-immuno-banner

Next Gen Immuno-Oncology Congress to be held on 13th and 14th March 2017 in London, UK aims to bring academicians, researchers and scientist from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the growth of existing therapeutics and pave way for emerging next generation therapeutics. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced.

URL: http://www.mnmconferences.com/Next-Gen-Immuno-Oncology-Congress

Contact Information: Amit Shelke (Email: amit.shelke@marketsandmarkets.com)

***
Quick-Links
***

Contact Us

Email-CON
 
Address-CON
 
Phone-CON
 
Web-CON
twitter
1px